Şirket yükleniyor
Just reported
Q3 2026 results
From Omnicell's results release of 29 Ekim 2026; its quarterly report has since been filed.
Revenue
Actual
$307,9M
-%0,9 y/y
-%1,4 q/qGuided
$304M
midpoint
Above guide+%1,3EPS, GAAP
Actual
$0,24
+%100 y/y
-%54 q/qGuided
—
No guide given
Operating income, GAAP
Actual
$14,9M
+%81 y/y
-%54 q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue$295M – $301M-%5,1 y/y First given
- EPS, adjusted$0,41 – $0,49First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Omnicell is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Health Information Services
Graded A or B and worth $2B or more: A first, then the largest.
VEEVVeeva Systems Inc.$48,9BA+
BTSGBrightSpring Health Services, Inc.$14,2BA
HNGEHinge Health, Inc.$9,4BA+
HQYHealthequity, Inc.$8,6BA+
DOCSDoximity, Inc.$5,9BB+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
Omnicell, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
